Clinical Trials | Research Study for Adults with Previously Untreated Mantle Cell Lymphoma

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have previously untreated mantle cell lymphoma (MCL). This study is investigating what happens to patients such as yourself with stage I-IV untreated mantle cell lymphoma who take both venetoclax and lenalidomide as well as receive rituximab injections. If you choose to take part in this study, your participation in this study will require up to 52 study visits over a 5-year period. Study involves taking an investigational drug combination, blood draws, an electrocardiogram, providing bone marrow and tissue biopsy samples (if not available from standard of care), pregnancy test (if woman of childbearing potential), and participation in the Revlimid Risk Evaluation and Mitigation Strategy program. You will also be asked if you would like to donate your samples to a specimen bank for future research and genetic research. Participant’s insurance company will be billed for medication, tests and procedures that are done as part of your standard of care. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: [email protected]